Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial
Translational Research Institute for Metabolism and Diabetes · Nelson Mandela Academic Hospital · +6 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
576
total citations
- FWCI
- 41.31
- Percentile
- 100%
- References
- 23
Citations per year
Authors
9- RERichard E. PratleyCorresponding
Translational Research Institute for Metabolism and Diabetes
- AAAslam Amod
Nelson Mandela Academic Hospital
- STSøren T. Hoff
Novo Nordisk (Denmark)
- TKTakashi Kadowaki
Teikyo University, The University of Tokyo
- ILIldiko Lingvay
The University of Texas Southwestern Medical Center
Topics & keywords
Topics
Keywords
- Semaglutide
- Liraglutide
- Medicine
- Placebo
- Type 2 diabetes
- Double blind
- Internal medicine
- Diabetes mellitus
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.